NSCLC
At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib.
At the moment, established personalized treatment approaches include treatment of patients with <span class="disease" id="22286583-4-96-101">NSCLC</span> and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of <span class="disease" id="22286583-4-258-263">NSCLC</span> patients with genetic aberrations in the <span class="gene" id="22286583-4-305-331">anaplastic lymphoma kinase</span> (<span class="gene" id="22286583-4-333-336">ALK</span>) oncogene with the mesenchymal-epithelial transition factor (MET)/<span class="gene" id="22286583-4-403-406">ALK</span> inhibitor crizotinib.